{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:47:22Z","timestamp":1792025242955,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for patients with type 2 diabetes (T2D) and obesity. However, their safety in patients with prior pancreatitis remains uncertain. This systematic review aims to evaluate the risk of recurrent acute pancreatitis (RAP) associated with GLP-1 RA therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched for studies evaluating the safety of GLP-1 receptor agonists in adults with type 2 diabetes mellitus (T2DM) or obesity and a history of acute pancreatitis. The primary outcome was recurrent acute pancreatitis. We included studies of adults with prior acute pancreatitis treated with GLP-1 receptor agonists for type 2 diabetes, obesity, or related metabolic conditions. Studies without recurrent acute pancreatitis outcomes, pediatric populations, overlapping cohorts, insufficient data, or non-original publications were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included four studies comprising 10,624 patients, of whom 5,427 (51.0%) received GLP-1 receptor agonists. Two studies provided comparative data (5,224 GLP-1 RA users; 5,197 controls). GLP-1 receptor agonist use was associated with lower odds of recurrent acute pancreatitis than placebo (OR 0.26, 95% CI 0.05\u20131.32) and lower risk than SGLT2 inhibitor use (OR 0.57, 95% CI 0.52\u20130.64). Two additional studies provided recurrence rates among GLP-1 RA users with prior pancreatitis, reporting rates of 9.9% (95% CI 5.8%\u201316.3%) and 11.9% (95% CI 5.1%\u201325.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Across the four included studies, GLP-1 receptor agonist use was not associated with an increase in RAP among patients with a prior history of acute pancreatitis. However, comparative evidence was limited to two studies, warranting cautious interpretation of these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00592-026-02809-y","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:12:06Z","timestamp":1792023126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of recurrent acute pancreatitis with GLP-1 receptor agonists after prior pancreatitis: a systematic review"],"prefix":"10.1007","author":[{"given":"Danielle L.","family":"Voltani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe G.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3061-9263","authenticated-orcid":false,"given":"Soemiwati","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"2","key":"2809_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14309\/ajg.0000000000003525","volume":"121","author":"LM Nieto","year":"2026","unstructured":"Nieto LM, Martinez J, Narvaez SI, Ko D, Kim DH, Vega KJ, Chawla S (2026) Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol 121(2):424\u2013431. https:\/\/doi.org\/10.14309\/ajg.0000000000003525","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2809_CR2","doi-asserted-by":"publisher","first-page":"103116","DOI":"10.1016\/j.dsx.2024.103116","volume":"18","author":"M Nassar","year":"2024","unstructured":"Nassar M, Nassar O, Abosheaishaa H, Misra A (2024) Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study. Diabetes Metab Syndr Clin Res Rev 18(9):103116. https:\/\/doi.org\/10.1016\/j.dsx.2024.103116","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"2","key":"2809_CR3","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.diabet.2025.101613","volume":"51","author":"M Nassar","year":"2025","unstructured":"Nassar M, Abosheaishaa H, Misra A, Dandona P, Ghanim H, Chaudhuri A (2025) Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis. Diabetes Metab 51(2):101613. https:\/\/doi.org\/10.1016\/j.diabet.2025.101613","journal-title":"Diabetes Metab"},{"issue":"10531","key":"2809_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M (2026) GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet 407(10531):892\u2013908. https:\/\/doi.org\/10.1016\/S0140-6736(25)02105-1","journal-title":"Lancet"},{"key":"2809_CR5","doi-asserted-by":"publisher","first-page":"bcp70512","DOI":"10.1002\/bcp.70512","volume":"5","author":"A Koren","year":"2026","unstructured":"Koren A, Koren L (2026) The pancreatic signal of GLP-1 receptor agonists: A biliary phenomenon rather than direct toxicity. Br J Clin Pharmacol Published online March 5:bcp70512. https:\/\/doi.org\/10.1002\/bcp.70512","journal-title":"Br J Clin Pharmacol Published online March"},{"key":"2809_CR6","doi-asserted-by":"publisher","first-page":"103991","DOI":"10.1016\/j.eclinm.2026.103991","volume":"96","author":"A Moiz","year":"2026","unstructured":"Moiz A, Peters TM, Tsoukas MA, Yu OHY, Filion KB, Eisenberg MJ (2026) Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making. eClinicalMedicine 96:103991. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103991","journal-title":"eClinicalMedicine"},{"issue":"5","key":"2809_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.pan.2025.06.018","volume":"25","author":"R Postlethwaite","year":"2025","unstructured":"Postlethwaite R, Amin AM, Alsawas R, Almandoz JP, Sawas T (2025) Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management. Pancreatology 25(5):609\u2013613. https:\/\/doi.org\/10.1016\/j.pan.2025.06.018","journal-title":"Pancreatology"},{"issue":"7","key":"2809_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2337\/dc16-2747","volume":"40","author":"WM Steinberg","year":"2017","unstructured":"Steinberg WM, Buse JB, Ghorbani MLM, \u00d8rsted DD, Nauck MA, the LEADER Steering Committee, on behalf of the LEADER Trial Investigators (2017) Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care 40(7):966\u2013972. https:\/\/doi.org\/10.2337\/dc16-2747","journal-title":"Diabetes Care"},{"key":"2809_CR9","doi-asserted-by":"publisher","first-page":"111806","DOI":"10.1016\/j.diabres.2024.111806","volume":"215","author":"LD Lomeli","year":"2024","unstructured":"Lomeli LD, Kodali AM, Tsushima Y, Mehta AE, Pantalone KM (2024) The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis. Diabetes Res Clin Pract 215:111806. https:\/\/doi.org\/10.1016\/j.diabres.2024.111806","journal-title":"Diabetes Res Clin Pract"},{"issue":"Supplement1","key":"2809_CR10","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"M Bajaj","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, Bennett AK, Beverly EA, Briggs Early K, ChallaSivaKanaka S, Echouffo-Tcheugui JB, Everett BM, Garg R, Laffel LM, Lal R, Matfin G, Nelson AB, Neumiller JJ, Pandya N, Pekas EJ, Peters AL, Pilla SJ, Romeo GR, Rosas SE, Sadhu AR, Segal AR, Simmons KM, Szmuilowicz ED, ElSayed NA (2026) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142026. Diabetes Care 49(Supplement1):S183\u2013S215. https:\/\/doi.org\/10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"issue":"9","key":"2809_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL, Kalyani RR, Kosiborod M, Magwire M, Morris PB, Neumiller JJ, Sperling LS (2020) 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. J Am Coll Cardiol 76(9):1117\u20131145. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.037","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2809_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3949\/ccjm.92a.24113","volume":"92","author":"AE Mehta","year":"2025","unstructured":"Mehta AE, Lomeli LD, Pantalone KM (2025) Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce. Cleve Clin J Med 92(8):483\u2013489. https:\/\/doi.org\/10.3949\/ccjm.92a.24113","journal-title":"Cleve Clin J Med"},{"issue":"apr15 2","key":"2809_CR13","doi-asserted-by":"publisher","first-page":"g2366","DOI":"10.1136\/bmj.g2366","volume":"348","author":"L Li","year":"2014","unstructured":"Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X (2014) Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 348(apr15 2):g2366\u2013g2366. https:\/\/doi.org\/10.1136\/bmj.g2366","journal-title":"BMJ"},{"issue":"2","key":"2809_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","volume":"103","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (2014) Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 103(2):269\u2013275. https:\/\/doi.org\/10.1016\/j.diabres.2014.01.010","journal-title":"Diabetes Res Clin Pract"},{"key":"2809_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol 134:178\u2013189. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.03.001","journal-title":"J Clin Epidemiol"},{"key":"2809_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ Published online August 28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ Published online August"},{"key":"2809_CR17","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"12","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ Published online Oct 12:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ Published online Oct"},{"key":"2809_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocr Pract 22:1\u2013203. https:\/\/doi.org\/10.4158\/EP161365.GL","journal-title":"Endocr Pract"},{"key":"2809_CR19","doi-asserted-by":"publisher","first-page":"1214334","DOI":"10.3389\/fendo.2023.1214334","volume":"14","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S (2023) Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 14:1214334. https:\/\/doi.org\/10.3389\/fendo.2023.1214334","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"17","key":"2809_CR20","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM et al (2020) Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5(17):e140532. https:\/\/doi.org\/10.1172\/jci.insight.140532","journal-title":"JCI Insight"},{"key":"2809_CR21","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.2147\/DDDT.S506957","volume":"19","author":"JS Min","year":"2025","unstructured":"Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK (2025) A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1\/GIP Receptor Agonist. Drug Des Devel Ther 19:3509\u20133537. https:\/\/doi.org\/10.2147\/DDDT.S506957","journal-title":"Drug Des Devel Ther"},{"key":"2809_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70116","author":"B Calvarysky","year":"2026","unstructured":"Calvarysky B, Gal Y, Kushnir S et al (2026) Glucagon-like peptide-1 analogues and the risk of recurrent pancreatitis in diabetic patients with history of pancreatitis or elevated lipase: retrospective cohort analysis. Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.70116","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"2809_CR23","doi-asserted-by":"publisher","first-page":"e2448","DOI":"10.1097\/MD.0000000000002448","volume":"95","author":"YK Lee","year":"2016","unstructured":"Lee YK, Huang MY, Hsu CY, Su YC (2016) Bidirectional relationship between diabetes and acute pancreatitis: a population-based cohort study in Taiwan. Med (Baltim) 95(2):e2448. https:\/\/doi.org\/10.1097\/MD.0000000000002448","journal-title":"Med (Baltim)"},{"issue":"4","key":"2809_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"21","key":"2809_CR25","doi-asserted-by":"publisher","first-page":"e194751","DOI":"10.1172\/JCI194751","volume":"135","author":"CK Wong","year":"2025","unstructured":"Wong CK, Drucker DJ (2025) Antiinflammatory actions of glucagon-like peptide-1\u2013based therapies beyond metabolic benefits. J Clin Invest 135(21):e194751. https:\/\/doi.org\/10.1172\/JCI194751","journal-title":"J Clin Invest"},{"issue":"6","key":"2809_CR26","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12885","volume":"19","author":"H Storgaard","year":"2017","unstructured":"Storgaard H, Cold F, Gluud LL, Vilsb\u00f8ll T, Knop FK (2017) Glucagon-like peptide\u20101 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab 19(6):906\u2013908. https:\/\/doi.org\/10.1111\/dom.12885","journal-title":"Diabetes Obes Metab"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02809-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02809-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02809-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:12:07Z","timestamp":1792023127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02809-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":26,"alternative-id":["2809"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02809-y","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"6 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required because this study is a systematic review of previously published studies and did not involve human participants or identifiable patient data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":3,"name":"Ethics","label":"<b>Disclosures<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}